![Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention | NEJM Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention | NEJM](https://www.nejm.org/na101/home/literatum/publisher/mms/journals/content/nejm/2005/nejm_2005.352.issue-11/nejmoa050405/production/images/img_medium/nejmoa050405_t1.jpeg)
Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention | NEJM
![Celecoxib loses its anti‐inflammatory efficacy at high doses through activation of NF‐κB - Niederberger - 2001 - The FASEB Journal - Wiley Online Library Celecoxib loses its anti‐inflammatory efficacy at high doses through activation of NF‐κB - Niederberger - 2001 - The FASEB Journal - Wiley Online Library](https://faseb.onlinelibrary.wiley.com/cms/asset/29311d6c-9ff3-48b2-8def-d7709620d1d4/fsb2fj000716fje-fig-0001-m.jpg)
Celecoxib loses its anti‐inflammatory efficacy at high doses through activation of NF‐κB - Niederberger - 2001 - The FASEB Journal - Wiley Online Library
![Celecoxib loses its anti‐inflammatory efficacy at high doses through activation of NF‐κB - Niederberger - 2001 - The FASEB Journal - Wiley Online Library Celecoxib loses its anti‐inflammatory efficacy at high doses through activation of NF‐κB - Niederberger - 2001 - The FASEB Journal - Wiley Online Library](https://faseb.onlinelibrary.wiley.com/cms/asset/d99ca0ed-fe46-42b8-be0c-cdbf63ce84f0/fsb2fj000716fje-fig-0003-m.jpg)
Celecoxib loses its anti‐inflammatory efficacy at high doses through activation of NF‐κB - Niederberger - 2001 - The FASEB Journal - Wiley Online Library
![Celecoxib loses its anti‐inflammatory efficacy at high doses through activation of NF‐κB - Niederberger - 2001 - The FASEB Journal - Wiley Online Library Celecoxib loses its anti‐inflammatory efficacy at high doses through activation of NF‐κB - Niederberger - 2001 - The FASEB Journal - Wiley Online Library](https://faseb.onlinelibrary.wiley.com/cms/asset/3b787d22-d470-4a61-bb4d-e472eac9a671/fsb2fj000716fje-fig-0004-m.jpg)
Celecoxib loses its anti‐inflammatory efficacy at high doses through activation of NF‐κB - Niederberger - 2001 - The FASEB Journal - Wiley Online Library
![Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention | NEJM Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention | NEJM](https://www.nejm.org/na101/home/literatum/publisher/mms/journals/content/nejm/2005/nejm_2005.352.issue-11/nejmoa050405/production/images/img_medium/nejmoa050405_f1.jpeg)
Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention | NEJM
![Enhanced sensitivity of celecoxib in human glioblastoma cells: Induction of DNA damage leading to p53-dependent G1 cell cycle arrest and autophagy | Molecular Cancer | Full Text Enhanced sensitivity of celecoxib in human glioblastoma cells: Induction of DNA damage leading to p53-dependent G1 cell cycle arrest and autophagy | Molecular Cancer | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2F1476-4598-8-66/MediaObjects/12943_2009_Article_451_Fig1_HTML.jpg)